The 5 linked references in paper L. Shpagina A., I. Shpagin S., O. Kotova S., T. Pospelova I., O. Gerasimenko N., Л. Шпагина А., И. Шпагин С., О. Котова С., Т. Поспелова И., О. Герасименко Н. (2017) “Дифференцированная терапия различных фенотипов хронической обструктивной болезни легких // Treatment of different phenotypes of chronic obstructive pulmonary disease” / spz:neicon:pulmonology:y:2016:i:6:p:681-693

  1. Kornmann O., Dahl R., Centanni S. et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebocontrolled comparison. Eur. Respir. J.2011; 37 (2): 273– 279. DOI: 10.1183/09031936.00045810.
  2. Wedzicha J.A., Singh D., Vestbo J. et al. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir. Med. 2014; 108 (8): 1153–1162. DOI:http://dx.doi.org/10.1016/j.rmed.2014.05.013.
  3. Agusti A., Bel E., Thomas M. et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur. Respir. J. 2016; 47 (2): 410–419. DOI: 10.1183/13993003.01359-2015.
  4. Suissa S., Dell'Aniello S., Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012; 67 (11): 957–963. DOI:10.1136/thoraxjnl-2011-201518.
  5. Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. TheTask Force for the management of arterial hypertension of the European Society ofHypertension (ESH) and of the European Society of Cardiology (ESC).J. Hypertens. 2013; 31 (7): 1281–1357.